Collaborate Disseminate
A new study published in the journal Neuropsychopharmacology has reported the results of the first modern clinical investigation to compare the acute effects of psychedelics LSD and psilocybin. The landmark study reveals little subjective difference be… Continue reading Landmark trial compares LSD and psilocybin trips, finds few differences
Just weeks after a double-blind, placebo-controlled trial found psilocybin microdosing to be no different to placebo, another study has been published that found LSD microdoses have no effect on mood or cognition. The new research builds on a small but… Continue reading Another trial finds no evidence LSD microdosing does anything
New research published in the Journal of Psychopharmacology has offered valuable insights into the long-term effects of psilocybin-assisted psychotherapy for depression. The study reports more than half the original cohort were still in remission 12 mo… Continue reading Psychedelic therapy for depression still effective one year later
Over the last couple of years, a novel cannabinoid has quietly grown in popularity. Delta-8 THC is similar to its more commonly known psychoactive cousin, delta-9 THC, but a legal loophole has led to its broad use across the United States despite safet… Continue reading What is delta-8 THC and is it a safe cannabis alternative?
With psychedelics well and truly hitting the mainstream, scientists are finally subjecting many anecdotal claims to the rigors of clinical research. The phenomenon of microdosing is one of those well-known psychedelic practices that many advocates arde… Continue reading No difference between psilocybin microdosing and placebo, trial finds
Results have been published from a first-of-its-kind clinical trial testing the effectiveness of ketamine infusions, combined with psychotherapy, in reducing the rate of relapse in people with severe alcoholism who have recently been detoxified. The la… Continue reading Clinical trial finds ketamine-assisted therapy helps treat alcoholism
A new study published in the The Journal of Psychopharmacology is reporting the results of a large clinical trial testing the short- and long-term safety of administering psilocybin in a group setting. Exploring the psychedelic therapy in groups of up to six people, the trial found no detrimental effects from simultaneous administration of the drug.
Category: Science
Tags: Psychedelic Medicine, Psychology, Drugs, King’s College London
Continue reading Psilocybin clinical trial confirms safety of group psychedelic sessions
As we get closer and closer to a world where psychedelic medicines are widely used in a variety of therapeutic ways, the last 12 months saw some incredible advances in the field of psychedelic science. From the first published data out of large-scale c… Continue reading Highlights from a landmark year in psychedelic science
Early data from the largest trial to date testing psilocybin therapy for depression indicates the psychedelic treatment may be somewhat effective at reducing symptom severity. However, concerns over some adverse effects indicate there is more work to b… Continue reading Largest psychedelic therapy trial to date delivers mixed results
Johns Hopkins Medicine has been awarded a US$4 million grant by the National Institutes of Health (NIH) to further clinical research investigating psilocybin-assisted psychotherapy to treat tobacco addiction. The grant is the first federal funding in h… Continue reading Psychedelic therapy research gets first US government funding in 50 years